IsoPlexis to Participate in the Evercore ISI HealthCONx Conference
11/24/2021 - 07:00 AM
BRANFORD, Conn. , Nov. 24, 2021 /PRNewswire/ -- IsoPlexis Corporation (Nasdaq: ISO), the leader in functional single-cell proteomics, today announced the company will be participating virtually in the upcoming Evercore ISI 4th Annual HealthCONx Conference.
IsoPlexis' management is scheduled to participate in a fireside chat on Wednesday, December 1 at 6:40 a.m. Pacific Time / 9:40 a.m. Eastern Time . Interested parties may access a live and archived webcast on the "Investors" section of the company website at: www.isoplexis.com .
About IsoPlexis
IsoPlexis is leading a new era of functional proteomics. By identifying our most proteomically active single cells (or "superhero cells") for the first time, IsoPlexis enables researchers to connect more directly to in vivo biology and develop more precise and personalized therapies. IsoPlexis has been named Top Innovation or Design by The Scientist Magazine, Fierce, BIG Innovation, Red Dot and multiple others. The IsoPlexis platform is used globally by researchers, including those at the top 15 global pharmaceutical companies and at the majority of leading U.S. comprehensive cancer centers.
Investor Contact investors@isoplexis.com
Press Contact press@isoplexis.com
https://www.prnewswire.com/news-releases/isoplexis-to-participate-in-the-evercore-isi-healthconx-conference-301431379.html
SOURCE IsoPlexis
IsoPlexis Corp
NASDAQ:ISO
ISO Rankings
N/A Ranked by Stock Gains
ISO Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
About ISO
IsoPlexis Corporation, a life sciences company, provides solutions for the development of curative medicines and personalized therapeutics in the United States and Europe. The company offers single cell proteomics platform, including instruments, chip consumables, and software that provides an end-to-end solution to view of protein function at an individual cellular level. It provides IsoLight and IsoSpark instruments; IsoCode chips that offer multiplexed chip solutions for single cell functional proteomics; CodePlex chips that provide multiplexed solutions for ultra-low volume bulk samples; and IsoSpeak software that offers dimensional data and automates analysis with an intuitive push button user interface to deliver same day single cell and bulk proteome visualizations without the need for highly specialized informatics professionals, as well as research support and services, and post-warranty services. The company was incorporated in 2013 and is based in Branford, Connecticut.
